Plaintiffs’ Executive, Steering Committees Established in Federal GranuFlo Lawsuit Litigation
GranuFlo lawsuit claims alleging life-threatening cardiovascular injuries and dialysis death are making headway in the federal multidistrict litigation (MDL) established in the District of Massachusetts, according to recent court documents.
The federal judge overseeing the proceeding, which housed at least 300 dialysis lawsuit flings over the acid concentrates as of July 16th, issued an Order that day establishing the multi-district litigation’s plaintiffs’ executive and steering committees. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
Cases filed in this litigation allege GranuFlo heart attack injuries, as well as cardiovascular death, sudden cardiac death and other side effects stemming from the medication administered during dialysis treatments. Dialysis death and other injuries allegedly caused by GranuFlo are experienced within 48 hours of the drugs’ administration.
Dialysis Death Lawsuit Filings Pile Up in Federal Court over GranuFlo
Distributed by Fresenius Medical Care, these dialysis medications were subject to a Class I recall in June 2012 by the U.S. Food and Drug Administration (FDA) after the agency found there to be reasonable chance they may cause severe side effects and/or death. According to a New York Times article published that summer, Fresenius treats more than one third of the approximate 400,000 American who receive dialysis treatments. The company also leads sales of disposable dialysis products and machines.
According to the report, GranuFlo and NaturaLyte were widely prescribed to patients in Fresenius-owned clinics, as well as those treated outside the company’s network. It is estimated that 125,000 patients were treated with GranuFlo outside the Fresenius network prior to the FDA recall.
Following its GranuFlo recall, the FDA launched an investigation last summer into whether Fresenius violated the law in waiting too long to recall the potentially dangerous products. This was after it was leaked in an internal memo from November 2011 that the company was aware of 900 deaths in patients who received GranuFlo or NaturaLyte. In the document, Fresenius officials advised doctors to adjust dosages of the drugs with this in mind.
The manufacturer then issued an Urgent Product Notification on March 29th, 2012 alerting the public of its products’ potential to cause cardiovascular death and other life-threatening injuries.
Join the Growing Number of Plaintiffs Who Have Already Filed GranuFlo Lawsuit Claims
If your loved one suffered a fatal side effect stemming from this dialysis drug, you should consider calling a GranuFlo lawyer at Bernstein Liebhard LLP who can help you file a claim. Contact the Firm at (877) 779-1414.